Abstract:Malak Alharbi, Muhammad Awidi, Grace K. Dy Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA Comment on: de Langen AJ, Johnson ML, Mazieres J, et al . Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 2023;401:733-46. Keywords: Non-small cell lung cancer (NSCLC); KRAS G12C; sotorasib; brain metastases; CodeBreak 200 (CB200) Submitted Aug 16, 2023. Accepted for publication Dec 08, 2023. Published online Jan 05, 2024. doi: 10.21037/tcr-23-1477 In recent years, groundbreaking advancements in lung cancer research have paved the way for innovative treatments directly targeting KRAS mutations, which have long erstwhile been considered undruggable due to their high substrate [guanosine triphosphate (GTP)] affinity in the picomolar range and lack of known regulatory binding sites. KRAS mutations in non-small cell lung cancer (NSCLC) occur in hotspots most frequently in exons 2 and 3, specifically at codons 12, 13, and 61, with variable biochemical properties across the different mutants (1). Notably, the KRAS p.G12C mutation, characterized by glycine (G) to cysteine (C) substitution at codon 12 which comprises around 40% of KRAS mutations found in NSCLC or 13–16% of known oncogenic drivers in NSCLC in the Western Hemisphere, maintains near normal levels of intrinsic GTP hydrolysis in contrast to other KRAS mutations, thus able to cycle between guanosine diphosphate (GDP)-bound (inactive) and GTP-bound (active) states. This genotype-specific biochemical feature, aside from advancements in structural analysis, set the stage for the generation of mutation-selective covalent inhibitors that can irreversibly bind to the GDP-bound (inactive) form of KRAS G12C (2). Sotorasib is the first-in-class agent in clinical development that covalently inhibits KRAS G12C by trapping it irreversibly in its inactive GDP-bound (OFF) conformation. In the phase 1/2 CodeBreak100 (CB100) trial, sotorasib demonstrated promising clinical efficacy and safety profile in patients with KRAS G12C mutated NSCLC who had been previously treated with at least one prior line of systemic therapy. This led to its accelerated approval by the United States Food and Drug Administration (US FDA) on May 28, 2021. Furthermore, sotorasib showcased its ability to provide durable clinical benefits on longer follow-up, revealing an overall response rate (ORR) of 41% and a 2-year overall survival (OS) rate of 33% (3). Encouraged by these findings, the phase 3 CodeBreak 200 (CB200) trial ensued, focusing on a head-to-head comparison of sotorasib 960 mg once daily vs. docetaxel 75 mg/m 2 every 3 weeks in patients previously treated for advanced KRAS p.G12C mutated NSCLC. CB200 is an open-label, randomized, multicenter study in which 330 patients aged 18 years and above were enrolled largely from sites outside of US (4). The trial included patients with locally unresectable or metastatic KRAS G12C mutated NSCLC following progression on at least one systemic therapy, including platinum-based chemotherapy and immune checkpoint inhibitor (unless contraindicated). Notably, patients with untreated, progressing, or symptomatic brain metastases were excluded from the study. While patients with known treated/stable brain metastases were enrolled and comprised approximately a third of enrolled patients in each group (sotorasib 33%; docetaxel 34.5%). Lastly, those with other actionable mutations for which approved therapies were available, such as EGFR or ALK, were excluded. The primary endpoint of progression-free survival (PFS), as determined by blinded independent central review (BICR), was achieved. With a median follow-up of 17.7 months, the median PFS was 5.6 months in the sotorasib arm compared to 4.5 months in the docetaxel arm [hazard ratio (HR), 0.66; 95% confidence interval (CI): 0.51–0.86; P=0.002]. Notably, the 12-month PFS rates were 24.8% and 10.1% for sotorasib and docetaxel, respectively. Furthermore, ORR was 28.1% in the sotorasib arm and 13.2% in the docetaxel arm (P<0.001). The disease control rates (DCRs) were 82.5% and 60.3% for sotorasib and docetaxel, respectively. Finally, the median duration of response (DOR) was 8.6 and 6.8 months for sotorasib and docetaxel, respectively. An important consideration when evaluating randomized studies is the choice of the comparator control arm. As a historical reminder, the REVEL trial demonstrated that the combination of docetaxel and ramucirumab provided a median OS benefit of 1.4 months over docetaxel alone (HR, 0.86; 95% CI: 0.75–0.98; P=0.023), albeit with increased treatment-emergent adverse events (5). The combination received US FDA approval for NSCLC second-line indication in December 2014. In the CB200 study, the use of single-agent docetaxel as the comparative control may -Abstract Truncated-

Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation

Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).

Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300.

Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)

Cost-effectiveness of Sotorasib As a Second-Line Treatment for Non-Small Cell Lung Cancer with KRASG12C Mutation in China and the US.

CodeBreak 200: study limitations, and future directions

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer.

First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety

A phase 1b study of sotorasib combined with panitumumab as second-line treatment of KRAS G12C - mutated colorectal cancer.

Sotorasib in KRAS G12C -Mutated Non-Small Cell Lung Cancer: A Multicenter Real-World Experience from the Compassionate Use Program in Germany

Sotorasib with panitumumab in chemotherapy-refractory KRAS G12C -mutated colorectal cancer: a phase 1b trial

Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator's choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).

Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: Insights from Pivotal Trials

Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States

FDA Approval Summary: Sotorasib for KRAS G12C Mutated Metastatic NSCLC.

D-1553 (garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients with NSCLC: Phase 1 Study Results.

Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced <i>RET</i> fusion-positive non-small-cell lung cancer and thyroid cancer, and <i>RET</i>-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial